European Commission Approves Johnson & Johnson’s Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

THOMSON REUTERS04-07

European Commission Approves Johnson & Johnson’s Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment